Post-earnings recap
Reported
Wed, Nov 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures. The stock fell 8.02% as investors reacted to the lack of revenue guidance and the overall cautious tone from management. The market may be concerned about the company's ability to navigate current challenges and deliver on its pipeline commitments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | +21.21% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the current environment. They remain focused on their long-term goals and pipeline development.
Management emphasized the ongoing challenges in the market.
They highlighted their commitment to advancing their pipeline despite current setbacks.